Loading stock data…
MAIA Biotechnology (MAIA)
$1.48+0.07 (+4.96%)
Market ClosedLast close Jun 29
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MAIA Biotechnology, Inc. in the Healthcare sector is trading at $1.48 with a market capitalization of $81M. Wall Street consensus targets $12.13 (2 analysts), implying a +719.9% move over the next 12 months. The stock is currently 54% below its 52-week high of $3.19, remaining 1.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +719.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.74M↓ | -$3.96M↑ | -$9.36M↓ | -$5.17M↑ | -$5.43M |
| Net Income | -$6.37M↓ | -$3.63M↑ | -$8.90M↓ | -$5.35M↓ | -$4.52M |
Peer Comparison
JNJUNHPFE
Fundamentals
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.34%
Volume
Today's trading volume
756,321
Recent News
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index increasing 0.6% and
Cancer drug maker takes sudden pivot into crypto
A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm. MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that its Board of Directors has approved allocating up to 90% of ...
Maia’s NSCLC immunotherapy secures Phase II efficacy win
The biotech is now running a Phase II expansion study to better evaluate the long-term benefits of ateganosine in third-line NSCLC.
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
The study will assess ateganosine in individuals who have been heavily pre-treated in third-line (3L) NSCLC.